By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

The Medicines Company 

8 Sylvan Way

Parsippany  New Jersey  07054  U.S.A.
Phone: 973-290-6000 Fax: 973-656-9898


SEARCH JOBS



The Medicines Company's purpose is to save lives, alleviate suffering and contribute to the economics of healthcare by focusing on 3,000 leading acute/intensive care hospitals worldwide. Its vision is to be a leading provider of solutions in three areas: acute cardiovascular care, surgery and perioperative care, and serious infectious disease care. The company operates in the Americas, Europe and the Middle East, and Asia Pacific regions with global centers today in Parsippany, NJ, USA and Zurich, Switzerland.



Key Statistics


Email: contactus@themedco.com
Ownership: Public

Web Site: The Medicines Company
Employees: 500+
Symbol: MDCO
 





Collaborations

Alnylam 





Company News
FDA Grants Accelerated Approval For The Medicines Company (MDCO)'s UTI Drug 8/30/2017 5:38:56 AM
Alnylam (ALNY) And The Medicines Company (MDCO) Release: New, One-Year Data From ORION-1 Phase II Study Of Inclisiran Extends Excellent Long-Term Efficacy And Safety Profile, Affirming Dose For Phase III Trials 8/28/2017 8:24:59 AM
The Medicines Company (MDCO) Reports Second Quarter 2017 Business And Financial Results 8/9/2017 6:42:55 AM
The Medicines Company (MDCO) To Announce Second-Quarter 2017 Financial Results On August 9 7/31/2017 6:43:02 AM
The Medicines Company (MDCO) Announces TANGO-2 Trial Of Meropenem-Vaborbactam (Formerly, Carbavance) Stopped Early For Superior Benefit-Risk Compared To Best Available Therapy For CRE 7/25/2017 10:25:28 AM
The Medicines Company (MDCO) To Present Data At ASM Microbe 2017 On Infectious Disease Portfolio Including Late-Stage Investigational Antibiotic Meropenem-Vaborbactam 5/31/2017 6:42:34 AM
The Medicines Company (MDCO) And Alnylam (ALNY) Announce Agreement With FDA On Phase III Clinical Program For Inclisiran 4/26/2017 6:21:54 AM
The Medicines Company (MDCO) Reports First-Quarter 2017 Financial Results 4/26/2017 6:01:58 AM
The Medicines Company (MDCO) To Present Data At ECCMID 2017 On Infectious Disease Portfolio Including Investigational Antibiotic Meropenem-Vaborbactam 4/17/2017 9:03:22 AM
The Medicines Company (MDCO) To Announce First-Quarter 2017 Financial Results On April 26, 2017 4/13/2017 8:09:18 AM
12345678910...
//-->